But it is still unclear whether this vaccine is needed, said Sabine Bruckner, head of Pfizer Switzerland, in an interview with “Blick”. Pfizer works in two directions.
On the one hand, the group is investigating how effective the previous vaccine is against the variants that are currently occurring. At the same time, Pfizer is analyzing whether an adjustment is needed and preparing it.
What can currently be said is that after the booster vaccination, the protection against omicron disease in adults is 25 times higher. Booster makes sense – especially to protect yourself from a serious course of the disease, said Bruckner.
Pfizer boss Bruckner: “Omicron vaccine would be ready within three months”(01:41)
Pfizer is in contact with the supervisory authority Swissmedic and the Federal Office of Public Health for the approval of antiviral pills. But there is still no antiviral therapy from Pfizer that has received approval in Switzerland. But she is confident that Pfizer will do business with the federal government.
Pfizer should have enough data by early 2022 that could be made available to Swissmedic to start the investigation. If all goes well, antiviral therapies could help relieve hospitals. (SDA)